Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)

M.D. Anderson Cancer Center1 enrolled

Overview

The goal of this study is to start treatment with the NOTCH1 inhibitor brontictuzumab in an attempt to control tumors and prolong survival. The therapy involves participant being given the drug brontictuzumab to treat adenoid cystic carcinoma (ACC) with NOTCH 1 mutations. This is considered an investigational treatment.

Treatment: Participant will receive brontictuzumab by vein over 30 minutes one time every 3 weeks. Clinic Visits: On Day 1 of Cycle 1 and then every 3 weeks from then on: * Participant will have a physical exam * Blood (about 3 teaspoons) will be drawn for routine tests. Every 6 weeks, participant will have an MRI and CT scan to check the status of the disease. Length of Treatment: Participant may continue taking brontictuzumab for as long as the doctor thinks it is in their best interest. Participant will no longer be able to take the drug if the disease gets worse, they develop another illness that prevents receiving more treatment, or if intolerable side effects occur. Brontictuzumab is not FDA approved or commercially available. It is currently being used for research purposes only.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Adenoid Cystic Carcinoma

Interventions

BrontictuzumabDRUG

1.5 mg/Kg intravenously every three weeks.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 2. Organ and marrow function as follows: absolute neutrophil count (ANC) ≥1000/mm3, platelets ≥50,000/dL, hemoglobin ≥8 g/dL, bilirubin ≤ 1.5 times the upper limit of normal, serum creatinine ≤1.5 mg/dL or creatinine clearance ≥50 mL/min, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal. 3. Central Nervous System (CNS) metastases allowed if subject does not require steroids, brain metastases are clinically stable without symptomatic progression 4. Capability to understand and comply with the protocol and signed informed consent document. Exclusion Criteria: 1. Major medical conditions that might affect study participation (e.g. uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection, cardiac disease) 2. Inability or unwillingness to abide by the study protocol or cooperate fully with the investigator.

Locations (1)

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Outcomes

Primary Outcomes

Number of Participants With Disease Progression

Tumor response for measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) to establish disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.